Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Opioid Growth Factor
100%
Multiple Sclerosis
100%
β-endorphin
100%
Physical Ability
100%
Serum Levels
33%
Multiple Sclerosis Treatment
33%
Composite Score
33%
Glatiramer Acetate
33%
Penn State
16%
Interleukin-17 (IL-17)
16%
Healthy Controls
16%
Vitamin D
16%
Treatment Group
16%
Blood-brain Barrier
16%
No Significant Difference
16%
Blood Samples
16%
Physical Health
16%
Potential Biomarkers
16%
Vitamin D Status
16%
Physical Disease
16%
Endogenous Opioid Peptides
16%
Disease Status
16%
Means of Control
16%
Degenerative Disease
16%
Disease-modifying Therapy
16%
Indirect Relationship
16%
Regression Data
16%
Cohort Data
16%
Serum Cytokines
16%
Minimally Invasive Biomarkers
16%
Peripheral Inflammation
16%
Relapsing-remitting multiple Sclerosis
16%
Natalizumab
16%
MSQOL-54
16%
Dimethyl Fumarate
16%
25-foot Walk Test
16%
State Health
16%
Healthcare Costs
16%
Autoimmune-mediated
16%
Immunology and Microbiology
Growth Factor
100%
Multiple Sclerosis
100%
Endorphin
100%
Blood Level
28%
Glatiramer Acetate
28%
Tumor Necrosis Factor
14%
Foot
14%
Cytokine
14%
Health Status
14%
Autoimmunity
14%
Blood Brain Barrier
14%
Vitamin Blood Level
14%
Peptides
14%
Relapsing Remitting Multiple Sclerosis
14%
Natalizumab
14%
Fumaric Acid Dimethyl Ester
14%
Inflammation
14%